Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 4
2019 10
2020 10
2021 11
2022 17
2023 8
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
New Antipsychotic Medications in the Last Decade.
Pahwa M, Sleem A, Elsayed OH, Good ME, El-Mallakh RS. Pahwa M, et al. Curr Psychiatry Rep. 2021 Nov 29;23(12):87. doi: 10.1007/s11920-021-01298-w. Curr Psychiatry Rep. 2021. PMID: 34843030 Review.
RECENT FINDINGS: We identified 11 significant developments: the introduction of new antipsychotics cariprazine, brexpiprazole, lumateperone, and pimavanserin; introduction of new delivery methods: subcutaneous long-acting risperidone, aripiprazole lauroxil, transdermal asenapine, …
RECENT FINDINGS: We identified 11 significant developments: the introduction of new antipsychotics cariprazine, brexpiprazole, lumateperone, …
Novel Compounds in the Treatment of Schizophrenia-A Selective Review.
Tsapakis EM, Diakaki K, Miliaras A, Fountoulakis KN. Tsapakis EM, et al. Brain Sci. 2023 Aug 11;13(8):1193. doi: 10.3390/brainsci13081193. Brain Sci. 2023. PMID: 37626549 Free PMC article. Review.
We discuss ten novel drugs, three of which have been approved by the FDA (Olanzapine/Samidorphan, Lumateperone, and Pimavanserin). The rest are under clinical trial investigation (Brilaroxazine, Xanomeline/Trospium, Emraclidine, Ulotaront, Sodium Benzoate, Luvadaxis …
We discuss ten novel drugs, three of which have been approved by the FDA (Olanzapine/Samidorphan, Lumateperone, and Pimavanser …
Olanzapine and samidorphan combination treatment: A systematic review.
Jawad MY, Alnefeesi Y, Lui LMW, Ceban F, Chen-Li DCJ, Teopiz K, Jaberi S, Gillissie ES, Vincenzo JDD, Rosenblat JD, McIntyre RS. Jawad MY, et al. J Affect Disord. 2022 Mar 15;301:99-106. doi: 10.1016/j.jad.2022.01.004. Epub 2022 Jan 7. J Affect Disord. 2022. PMID: 35007644 Review.
INTRODUCTION: The overarching aim of this review is to synthesize the efficacy, tolerability, and weight-mitigation effects of the olanzapine/samidorphan (OLZ/SAM) combination treatment in adults with schizophrenia and bipolar disorder-I. ...
INTRODUCTION: The overarching aim of this review is to synthesize the efficacy, tolerability, and weight-mitigation effects of the olanza …
Olanzapine/Samidorphan: New Drug Approved for Treating Bipolar I Disorder and Schizophrenia.
Monahan C, McCoy L, Powell J, Gums JG. Monahan C, et al. Ann Pharmacother. 2022 Sep;56(9):1049-1057. doi: 10.1177/10600280211070330. Epub 2022 Jan 18. Ann Pharmacother. 2022. PMID: 35040357 Review.
DATA SOURCES: A literature search of PubMed was performed (March 2006 to November 2021) using the following search terms: Lybalvi, olanzapine/samidorphan, olanzapine, antipsychotic, bipolar disorder, and schizophrenia. ...Additional studies are needed to furt …
DATA SOURCES: A literature search of PubMed was performed (March 2006 to November 2021) using the following search terms: Lybalvi, olanza …
Olanzapine/Samidorphan: First Approval.
Paik J. Paik J. Drugs. 2021 Aug;81(12):1431-1436. doi: 10.1007/s40265-021-01568-0. Drugs. 2021. PMID: 34304374 Review.
Olanzapine/samidorphan (LYBALVI()) was recently approved in the USA for the treatment of schizophrenia and bipolar I disorder. This article summarizes the milestones in the development of samidorphan leading to this first approval of olanzapine/sami …
Olanzapine/samidorphan (LYBALVI()) was recently approved in the USA for the treatment of schizophrenia and bipolar I disorder. …
Olanzapine/Samidorphan: A New Combination Treatment for Schizophrenia and Bipolar I Disorder Intended to Reduce Weight Gain.
Corrao MM, Nelson LA. Corrao MM, et al. CNS Drugs. 2022 Jun;36(6):605-616. doi: 10.1007/s40263-022-00923-3. Epub 2022 May 30. CNS Drugs. 2022. PMID: 35644903 Review.
Olanzapine/samidorphan demonstrated similar efficacy as olanzapine monotherapy and was well tolerated. ...Olanzapine/samidorphan is an effective treatment for schizophrenia and bipolar I disorder with less weight gain than olanzapine mono …
Olanzapine/samidorphan demonstrated similar efficacy as olanzapine monotherapy and was well tolerated. ...Olanzapine …
Combination Olanzapine and Samidorphan for the Management of Schizophrenia and Bipolar 1 Disorder in Adults: A Narrative Review.
Haddad HW, Boardman E, Williams B, Mouhaffel R, Kaye AM, Kaye AD. Haddad HW, et al. Health Psychol Res. 2022 Apr 25;10(3):34224. doi: 10.52965/001c.34224. eCollection 2022. Health Psychol Res. 2022. PMID: 35774916 Free PMC article. Review.
Samidorphan mitigates the weight gain side effects of olanzapine by antagonizing mu-, kappa-, and delta-opioid receptors. The use of combination drugs to treat psychiatric conditions is an emerging field with the goal of increasing therapeutic efficacy and decreasin …
Samidorphan mitigates the weight gain side effects of olanzapine by antagonizing mu-, kappa-, and delta-opioid receptors. The …
Olanzapine-Samidorphan for Schizophrenia: A Systematic Review and Meta-Analysis.
Gupta D, Singh A. Gupta D, et al. Indian J Psychol Med. 2024 Jan;46(1):14-23. doi: 10.1177/02537176231201326. Epub 2023 Oct 22. Indian J Psychol Med. 2024. PMID: 38524957 Free PMC article. Review.
BACKGROUND AND OBJECTIVE: United States Food and Drug Administration (USFDA) recently approved a novel combination of olanzapine-samidorphan (OLZSAM) for managing olanzapine-associated adverse events (weight gain) in adult patients with schizophrenia and bipo …
BACKGROUND AND OBJECTIVE: United States Food and Drug Administration (USFDA) recently approved a novel combination of olanzapine-s …
Samidorphan/olanzapine combination therapy for schizophrenia: Efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials.
Rehan ST, Siddiqui AH, Khan Z, Imran L, Syed AA, Tahir MJ, Jassani Z, Singh M, Asghar MS, Ahmed A. Rehan ST, et al. Ann Med Surg (Lond). 2022 Jun 30;79:104115. doi: 10.1016/j.amsu.2022.104115. eCollection 2022 Jul. Ann Med Surg (Lond). 2022. PMID: 35860157 Free PMC article. Review.
Recently, FDA approved a combination dose of olanzapine and samidorphan (OLZ/SAM) to mitigate the adverse outcomes associated with olanzapine use for the treatment of Schizophrenia. OBJECTIVES: The approval of olanzapine/samidorphan combination …
Recently, FDA approved a combination dose of olanzapine and samidorphan (OLZ/SAM) to mitigate the adverse outcomes associated …
Olanzapine-samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used?
Faden J, Serdenes R, Citrome L. Faden J, et al. Expert Rev Neurother. 2022 May;22(5):365-376. doi: 10.1080/14737175.2022.2060742. Epub 2022 Apr 13. Expert Rev Neurother. 2022. PMID: 35354374 Review.
Olanzapine-samidorphan combination tablets (OLZ/SAM), branded as Lybalvi, is a newly FDA approved formulation aimed at attenuating antipsychotic induced weight gain via modulation of the endogenous opioid system with samidorphan, while retaining the robust an …
Olanzapine-samidorphan combination tablets (OLZ/SAM), branded as Lybalvi, is a newly FDA approved formulation aimed at attenua …
59 results